Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.

Furthermore, sEVs appeared to reverse the antitumor efficacy of dinutuximab plus tipifarnib ( figure 6B–D ), although the result did not reach statistical significance (p=0.086).

also in 111,027 other papers